Fig. 2
SREBP2 is a negative regulator of osteoclastogenesis. a Srebp2 mRNA levels were assessed by qPCR from SREBP2WT and SREBP2∆M BMMs. b–e SREBP2WT and SREBP2∆M BMMs cultured with RANKL (50 ng/mL) for three days. b Immunoblots of nuclear lysates using SREBP2 and Lamin B antibodies. c Cells were TRAP-stained (left) and counted for 3 or more nuclei (right). Scale bars: 100 µm. d Bone resorption activity wase assessed by culturing SREBP2WT and SREBP2∆M BMMs with RANKL (50 ng/mL). Scale bars: 500 µm. e Osteoclast marker genes were assessed after RANKL (50 ng/mL) stimulation for 3 days. f SREBP2WT and SREBP2∆M BMMs transduced with adenoviruses harboring GFP control or FLAG_N_SREBP2 (SREBP2) were cultured with RANKL (50 ng/mL) (left). Scale bars: 100 µm. TRAP-positive cells with 3 or more nuclei were counted (right). All data are shown as median and interquartile range. n.s., not significant; *P < 0.05; **P < 0.01; ***P < 0.001 by paired t test (a, c, d) or two-way ANOVA with multiple comparisons (e, f). All data are from at least 3 independent experiments
